In another ongoing phase I clinical trial (NCT03198546), complete tumor disappearance was observed in patients with GPC3+ advanced HCC after 30 days of treatment with intratumor injections of 19.9 × 108 CAR-GPC3 T cells (169). This evidence concerns the gene GPC3 and neoplasm.